Cantor Fitzgerald Maintains Organogenesis(ORGO.US) With Buy Rating, Raises Target Price to $6
Lake Street Maintains Organogenesis(ORGO.US) With Buy Rating, Maintains Target Price $5
Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Organogenesis Holdings (ORGO)
BTIG Maintains Organogenesis(ORGO.US) With Buy Rating, Raises Target Price to $7
Morgan Stanley Initiates Organogenesis(ORGO.US) With Hold Rating, Announces Target Price $4
Morgan Stanley Sticks to Their Hold Rating for Organogenesis Holdings (ORGO)
Cantor Fitzgerald Maintains Organogenesis(ORGO.US) With Buy Rating, Raises Target Price to $3.8
Lake Street Maintains Organogenesis(ORGO.US) With Buy Rating, Maintains Target Price $5
BTIG Maintains Organogenesis(ORGO.US) With Buy Rating, Maintains Target Price $6
Lake Street Maintains Organogenesis(ORGO.US) With Buy Rating, Maintains Target Price $5
Lake Street Maintains Organogenesis(ORGO.US) With Buy Rating, Maintains Target Price $5
Organogenesis Holdings (ORGO) Receives a Buy From Lake Street
Cantor Fitzgerald Maintains Organogenesis(ORGO.US) With Buy Rating, Maintains Target Price $3.5
Organogenesis Holdings (ORGO) Receives a Buy From Cantor Fitzgerald
Organogenesis Hldgs Analyst Ratings
Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating
Buy Rating Affirmed for Organogenesis Holdings Amid Stable Product Pricing and Positive Market Dynamics
Organogenesis Hldgs Analyst Ratings
Organogenesis Holdings: A Buy Rating With Anticipated Turnaround and Growth Prospects
Organogenesis Hldgs Analyst Ratings
Unlock the Full List